May 14th 2024
The phase 3 KeyVibe-010 trial is unlikely to meet its primary end point of recurrence-free survival due to a high rate of treatment discontinuation.
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Immune, Targeted Therapies Plus Radiation Ups Survival in Melanoma Patients With Brain Metastases
September 30th 2016Researchers at Moffitt Cancer Center in Tampa, Fla., demonstrated how novel immune and targeted therapies with radiation therapy may improve the outcomes of patients with melanoma who have brain metastases.
Encorafenib and Binimetinib Combo May Help Improve Survival in Patients With BRAF-Mutant Melanoma
September 28th 2016Combining the BRAF inhibitor encorafenib with the MEK inhibitor binimetinib may significantly improve progression-free survival in BRAF mutant melanoma, according to a new phase III trial.